Oruka Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
68
- Stock Symbol
-
ORKA
- Investments
-
1
- Share Price
-
$95.81
- (As of Friday Closing)
Oruka Therapeutics General Information
Description
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Contact Information
Website
www.orukatx.comCorporate Office
- 203 Crescent Street Building 21
- Suite 203
- Waltham, MA 02453
- United States
Corporate Office
- 203 Crescent Street Building 21
- Suite 203
- Waltham, MA 02453
- United States
Oruka Therapeutics Timeline
Oruka Therapeutics Stock Performance
As of 20-Nov-2026, Oruka Therapeutics’s stock price is $95.81. Its current market cap is $6.5B with 67.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $95.81 | $97.45 | $25.23 - $115.52 | $6.5B | 67.8M | 965K | -$2.12 |
Oruka Therapeutics Financials Summary
As of 30-Sep-2026, Oruka Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 4,646,519 | 1,122,972 | ||
| Revenue | 0 | 0 | ||
| EBITDA | (182,929) | (121,980) | ||
| Net Income | (152,574) | (105,433) | ||
| Total Assets | 1,231,026 | 488,617 | 37,900 | 43,100 |
| Total Debt | 2,932 | 1,932 | 0 | 0 |
Oruka Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oruka Therapeutics Signals
Oruka Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Oruka Therapeutics Acquisitions (1)
Oruka Therapeutics’s most recent deal was a Merger/Acquisition with Arca Biopharma. The deal was made on 29-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arca Biopharma | 29-Aug-2024 | Merger/Acquisition | Drug Discovery |
Oruka Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Oruka Therapeutics FAQs
-
When was Oruka Therapeutics founded?
Oruka Therapeutics was founded in 2015.
-
Where is Oruka Therapeutics headquartered?
Oruka Therapeutics is headquartered in Waltham, MA.
-
What is the size of Oruka Therapeutics?
Oruka Therapeutics has 68 total employees.
-
What industry is Oruka Therapeutics in?
Oruka Therapeutics’s primary industry is Drug Discovery.
-
Is Oruka Therapeutics a private or public company?
Oruka Therapeutics is a Public company.
-
What is Oruka Therapeutics’s stock symbol?
The ticker symbol for Oruka Therapeutics is ORKA.
-
What is the current stock price of Oruka Therapeutics?
As of 20-Nov-2026 the stock price of Oruka Therapeutics is $95.81.
-
What is the current market cap of Oruka Therapeutics?
The current market capitalization of Oruka Therapeutics is $6.5B.
-
What is Oruka Therapeutics’s annual earnings per share (EPS)?
Oruka Therapeutics’s EPS for 12 months was -$2.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process